IP Library Granted Patent US 7,682,803
Granted Patent B2
US 7,682,803 · App. 11/580,588 · Granted Mar 23, 2010

Immunomodulation using placental stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,682,803
App. No.
11/580,588
Granted
Mar 23, 2010
Kind
B2
Abstract

The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.

Claims (14)

1. A method of suppressing an immune response comprising contacting a plurality of T cells or natural killer (NK) cells with 1 million to 10 billion placental stem cells for a time sufficient for said placental stem cells to detectably suppress an immune response, wherein said placental stem cells detectably suppress T cell proliferation stimulated by Epstein-Barr virus antigen-presenting B cells; and

wherein at least 80% of said 1 million to 10 billion said placental stem cells express CD200.

2. The method of claim 1 , wherein said T cells are CD4 + T cells.

3. The method of claim 1 , wherein said T cells are CD8 + T cells.

4. The method of claim 1 , wherein said contacting is performed in vitro.

5. The method of claim 1 , wherein said plurality of placental stem cells comprises 1×10 6 placental stem cells.

6. The method of claim 1 , wherein said plurality of placental stem cells comprises 1×10 7 placental stem cells.

7. The method of claim 1 , wherein said plurality of placental stem cells comprises 1×10 8 placental stem cells.

8. The method of claim 1 , wherein said at least 80% of said 1 million to 10 billion said placental stem cells are OCT-4 + .

9. The method of claim 1 , wherein said at least 80% of said 1 million to 10billion said placental stem cells are one or more of CD34 − , CD38 − , or CD45 − .

10. The method of claim 8 , wherein said at least 80% of said 1 million to 10 billion said placental stem cells are one or more of CD34 − , CD38 − , or CD45 − .

11. The method of claim 1 , wherein said at least 80% of said 1 million to 10 billion said placental stem cells are CD10 + or CD105 + .

12. The method of claim 8 , wherein said at Least 80% of said 1 million to 10 billion said placental stem cells are CD10 + or CD105 + .

13. The method of claim 1 , wherein said at least 80% of said 1 million to 10billion said placental stem cells are CD10 + , CD34 − , CD105 + and CD200 + .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: PALUDAN, CASPER; EDINGER, JAMES; HARBACHEUSKI, RYHOR; MURRAY, ROSEANN; HARIRI, ROBERT J
To: ANTHROGENESIS CORPORATION
Reel/Frame 019223/0652 →